Head-To-Head Comparison: Global Cord Blood (NYSE:CORBF) & Mangoceuticals (NASDAQ:MGRX)

Global Cord Blood (NYSE:CORBF) and Mangoceuticals (NASDAQ:MGRX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Global Cord Blood and Mangoceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Global Cord Blood	0	0	0	0	N/A
Mangoceuticals	0	0	0	0	N/A

Volatility & Risk

Global Cord Blood has a beta of -0.26, suggesting that its stock price is 126% less volatile than the S&P 500. Comparatively, Mangoceuticals has a beta of 2.1, suggesting that its stock price is 110% more volatile than the S&P 500.

Valuation and Earnings

This table compares Global Cord Blood and Mangoceuticals’ top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Global Cord Blood	$196.12 million	N/A	$79.04 million	N/A	N/A
Mangoceuticals	$730,000.00	10.21	-$9.21 million	N/A	N/A

Global Cord Blood has higher revenue and earnings than Mangoceuticals.

Institutional & Insider Ownership

56.7% of Mangoceuticals shares are owned by institutional investors. 0.5% of Global Cord Blood shares are owned by company insiders. Comparatively, 39.3% of Mangoceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Global Cord Blood and Mangoceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Global Cord Blood	N/A	N/A	N/A
Mangoceuticals	-1,068.72%	-864.10%	-577.68%

Summary

Global Cord Blood beats Mangoceuticals on 5 of the 8 factors compared between the two stocks.

About Global Cord Blood

Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2022, it operated three cord blood banks, including one in the Beijing municipality; one in the Guangdong province; and one in the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation operates as a subsidiary of Blue Ocean Structure Investment Company Ltd.

About Mangoceuticals

Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.